Novel Treatment Approaches in Moderate-to-Severe Rheumatoid Arthritis (RA): Expert Perspectives on an Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive

This activity is valid from May 1, 2020 to May 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie, Bristol-Myers Squibb, and Gilead

Description:
Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. According to the American College of Rheumatology (ACR), it is estimated that over 1.3 million people suffer from RA in the United States. The disease may also affect other parts of the body, which results in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fortunately for patients with RA, several new medications have become available recently that have shown improved efficacy and safety and offer options for those who are intolerant to anti-TNF therapies.

Upon completion of this activity, participants will be able to:

  • Describe the clinical, social, and economic burden of rheumatoid arthritis (RA) and its impact on health systems populations

  • Analyze the safety and efficacy of current and emerging therapies, including JAK inhibitors and IL-6 inhibitors, in the treatment of moderate-to-severe RA for achieving individualized treatment goals

  • Explore methods to integrate new and emerging JAK inhibitors into moderate-to-severe RA-treatment algorithms based on guideline recommendations, recent clinical trial data, and patient preferences

  • Critically evaluate data regarding the utility of RA biomarkers, such as ACPAs, and their assays in the early diagnosis of RA and its personalized management

  • Discuss adverse events associated with new and emerging JAK inhibitors and IL-6 inhibitors in RA, and explore appropriate strategies that help ensure patient treatment adherence and optimum quality of life

  • Assess the managed care considerations of current and emerging biologic therapies in the management of RA and the effect they have on the current moderate-to-severe RA management paradigm
     

Faculty: Allan Gibofsky, MD, JD
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery

Disclosure:

Dr. Gibofsky serves on an advisory board and is a consultant for AbbVie, Gilead, Lilly, Novartis, and Pfizer. He serves on the speaker's bureau for AbbVie, Lilly, Novartis, and Pfizer. He owns and self-manages stock in AbbVie, BMS, Lilly, and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie, Bristol-Myers Squibb, and Gilead

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue